The Brazil Clinical Trial Imaging Market was valued at $34.63 Million in 2024 and projected to reach to $48.87 Million by 2029, representing a compound annual growth rate of 7.1%. Brazil's clinical trial imaging market is poised for sustained growth as the country strengthens its position as Latin America's premier clinical research destination.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Brazil's clinical trial imaging market is valued at USD 34.63 million in 2024, with projections reaching USD 48.87 million by 2029, representing a robust 7.1% CAGR specific to the Brazilian market.
Brazil maintains its position as the leading clinical research hub in Latin America, driven by advanced healthcare infrastructure, skilled research professionals, and a large patient population suitable for diverse trial protocols.
Brazil's regulatory framework continues to modernize, with ANVISA (National Health Surveillance Agency) implementing streamlined approval processes that accelerate clinical trial initiation and imaging protocol standardization.
Increasing pharmaceutical and biotech investments in Brazil's research infrastructure are expanding imaging capabilities, including advanced MRI, CT, and digital pathology technologies essential for multi-center trial operations.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | ONCOLOGY (Therapeutic Area) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 7.8% from 2024 to 2029 |
| Largest Segment | SERVICES (Service & Software) |
| Market Size Base Year (Billions) | ~USD 1.42 (2024) |
| Revenue Forecast (Billions) | ~USD 2.07 (2029) |
| Segments Covered | Service & Software, Type, Modality, Therapeutic Area, End User |
5 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES | 1.06 | 1.15 | 1.2 | 1.26 | 1.32 | 1.38 | 1.46 | 1.54 | 5.1 |
| CONTRACT RESEARCH ORGANIZATIONS | 3.24 | 3.54 | 3.72 | 3.92 | 4.13 | 4.36 | 4.62 | 4.89 | 5.6 |
| MEDICAL DEVICE MANUFACTURERS | 5.33 | 5.84 | 6.16 | 6.52 | 6.9 | 7.32 | 7.77 | 8.28 | 6.1 |
| OTHER END USERS | 0.87 | 0.94 | 0.98 | 1.02 | 1.06 | 1.11 | 1.16 | 1.22 | 4.5 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 28.21 | 31.19 | 33.16 | 35.32 | 37.71 | 40.32 | 43.18 | 46.33 | 6.9 |
| TOTAL | 38.71 | 42.66 | 45.22 | 48.04 | 51.12 | 54.49 | 58.19 | 62.26 | 6.6 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| PATHEON INC | Netherlands | Private Company | Drug product services (finished dosage manufacturing, packaging, lifecycle),Pharmaceutical development services (formulation, analytical, clinical supply),Drug substance services (small- and large-molecule APIs), |
| BIOMERIEUX S.A. | France | Public Company | Clinical microbiology (VITEK, culture media, BACT/ALERT, ETEST, API),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA), |
| TAKE SOLUTIONS | India | Public Company | Clinical research and data sciences,Pharmacovigilance, safety, and regulatory affairs,Generics development services, |
| BRUKER CORPORATION | United States | Public Company | BSI BioSpin (NMR, EPR, preclinical imaging),BSI CALID (mass spectrometry, molecular diagnostics, automation),BSI Nano (X-ray, AFM, electron microscopy tools), |
| SANOFI | France | Public Company | Vaccines (pediatric, RSV, hexavalent, travel),Immunology & Inflammation,Rare Diseases & Neurology, |
| MEDIDATA SOLUTIONS | United States | Private Company | Core clinical data capture and management (EDC, CTMS, monitoring),Decentralized trial and patient engagement solutions,Data analytics and insights offerings, |
| ZENSAR TECHNOLOGIES LTD | India | Public Company | Digital and Application Services,Cloud Infrastructure and Security Services,Brand, Marketing, and Consulting Services, |
| TENET HEALTHCARE CORPORATION | United States | Public Company | Hospital Operations and Services,Ambulatory Care (ASCs and Surgical Hospitals),Other Outpatient and Ancillary Services, |
| UNITED IMAGING HEALTHCARE CO., LTD. | China | Public Company | Magnetic Resonance Imaging,Computed Tomography,Molecular Imaging (PET/CT, SPECT), |
| ICON PLC | Ireland | Public Company | Clinical development services (Phase I–IV, peri/post-approval),Functional service partnerships & contract staffing,Laboratory and testing services (bioanalytical, biomarker, central labs, vaccine, GMP), |
| MEDPACE | United States | Public Company | Full-service clinical development (Phase I–IV),Central and bio-analytical laboratory services,Specialized services (imaging, ECG, human pharmacology), |
| IXICO PLC | United Kingdom | Public Company | Imaging CRO services (biomarkers, reads, trial management),AI-enabled IXICO platform and data analytics,Post-marketing surveillance, clinical diagnostics, and consultancy, |
| RESONANCE HEALTH LTD. | Australia | Public Company | FerriScan and CardiacT2 LIC/iron-loading services,AI SaMD (FerriSmart, HepaFatSmart, LiverSmart),HepaFatScan and related liver-fat MRI services, |
| WCG CLINICAL | United States | Private Company | Regulatory and ethical review / human research protections,Technology platforms (eConsent, AIMS, Velos eResearch eXpress),Consulting, biosafety, and online learning, |
Patheon Inc is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and life sciences sector.
bioMérieux S.A. is a French public company founded in 1963 with 14,894 employees specializing in in vitro diagnostics and microbiology testing solutions.
Take Solutions is an India-based public company founded in 2000 with 2 employees providing business and technology services.
Bruker Corporation is a United States-based public company founded in 1960 with 11,085 employees manufacturing scientific instruments and analytical solutions.
Sanofi is a French multinational public pharmaceutical company founded in 1994 with 74,846 employees engaged in drug discovery, development, and manufacturing.
Medidata Solutions is a United States-based private company founded in 1999 with 1,998 employees providing cloud-based clinical trial software and services.
Zensar Technologies Ltd is an India-based public company founded in 1963 with 10,066 employees providing IT services and digital transformation solutions.
Tenet Healthcare Corporation is a United States-based public company founded in 1967 with 88,500 employees operating a large network of hospitals and healthcare facilities.
United Imaging Healthcare Co., Ltd. is a China-based public company founded in 2011 with 8,703 employees manufacturing medical imaging equipment and healthcare solutions.
ICON PLC is an Ireland-based public company founded in 1989 with 40,350 employees providing clinical research and drug development services.
Medpace is a United States-based public company founded in 1992 with 6,300 employees offering clinical research and development services.
IXICO PLC is a United Kingdom-based public company with 79 employees specializing in medical imaging analysis and clinical trial services.
Resonance Health Ltd. is an Australia-based public company founded in 1987 with 16 employees providing medical imaging analysis and software solutions.
WCG Clinical is a United States-based private company founded in 1968 with 1,342 employees providing clinical research and trial management services.
Brazil's clinical trial imaging market was valued at USD 34.63 million in 2024 and is expected to grow to USD 48.87 million by 2029.
Brazil's clinical trial imaging market is projected to grow at a compound annual growth rate (CAGR) of 7.1% from 2024 to 2029.
Brazil is Latin America's leading clinical research hub, with a large patient population, established regulatory framework, and growing investment in pharmaceutical research infrastructure that drives imaging technology adoption.
Brazil's clinical trials primarily utilize MRI, CT, and ultrasound imaging systems configured specifically for trial protocols to support efficacy assessment and patient safety monitoring.
Multinational pharmaceutical companies, domestic contract research organizations (CROs), and government-supported research institutions are the primary drivers of imaging technology adoption in Brazil.
The objective of the study is to analyze the key market dynamics, such as drivers, opportunities, challenges, restraints, and key player strategies. To track company developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships of the leading players, the competitive landscape of the clinical trial imaging market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, market breakdown and data triangulation were used.
The four steps involved in estimating the market size are:
The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical trial imaging market. A database of the key industry leaders was also prepared using secondary research.
The primary research data was conducted after acquiring knowledge about the clinical trial imaging market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as hospitals & ICUs, diagnostic laboratories, research institutes, research laboratories and point-of-care settings) and supply side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Approximately 40% of the primary interviews were conducted with stakeholders from the demand side, while those from the supply side accounted for the remaining 60%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.
A breakdown of the primary respondents is provided below:
Note 1: *Others include sales managers, marketing managers, and product managers.
Note 2: Tiers are defined based on a company’s total revenue as of 2022: Tier 1=> USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3=< USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
All major product manufacturers offering various clinical trial imaging products were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value clinical trial imaging market was also split into various segments and subsegments at the region and country level based on:

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the clinical trial imaging industry.
Clinical trial Imaging is used to create images during clinical trials while conducting research. Such imaging testing is mainly done using X-rays, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and positron emission tomography (PET). In clinical trials, imaging is used primarily to evaluate efficacy, endpoints, and more frequently, for safety evaluations and eligibility criteria.
Full forecast, segment splits, and company analysis for all Clinical Trial Imaging Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report